SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy.
Saved in:
| Title: | SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy. |
|---|---|
| Authors: | Cini JK; Sonnet BioTherapeutics, Inc., Princeton, NJ, United States., Kenney RT; Sonnet BioTherapeutics, Inc., Princeton, NJ, United States., Dexter S; Sonnet BioTherapeutics, Inc., Princeton, NJ, United States., McAndrew SJ; Sonnet BioTherapeutics, Inc., Princeton, NJ, United States., Eraslan RN; Disease Modeling and Oncology, Invivotek, Hamilton, NJ, United States., Brody R; InfinixBio, Inc., Athens, OH, United States., Rezac DJ; Latham Biopharm Group, Inc., Elkridge, MD, United States., Boohaker R; Southern Research, Birmingham, AL, United States., Lapi SE; Radiology, Chemistry, and Biomedical Engineering, University of Alabama, Birmingham, AL, United States., Mohan P; Sonnet BioTherapeutics, Inc., Princeton, NJ, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2024 Dec 04; Vol. 15, pp. 1493257. Date of Electronic Publication: 2024 Dec 04 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1493257 |
